Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial

BACKGROUND: Third-generation chimeric antigen receptor (CAR)-engineered T cells (CARTs) might improve clinical outcome of patients with B cell malignancies. This is the first report on a third-generation CART dose-escalating, phase-1/2 investigator-initiated trial treating adult patients with refrac...

Descripción completa

Detalles Bibliográficos
Autores principales: Schubert, Maria-Luisa, Schmitt, Anita, Hückelhoven-Krauss, Angela, Neuber, Brigitte, Kunz, Alexander, Waldhoff, Philip, Vonficht, Dominik, Yousefian, Schayan, Jopp-Saile, Lea, Wang, Lei, Korell, Felix, Keib, Anna, Michels, Birgit, Haas, Dominik, Sauer, Tim, Derigs, Patrick, Kulozik, Andreas, Kunz, Joachim, Pavel, Petra, Laier, Sascha, Wuchter, Patrick, Schmier, Johann, Bug, Gesine, Lang, Fabian, Gökbuget, Nicola, Casper, Jochen, Görner, Martin, Finke, Jürgen, Neubauer, Andreas, Ringhoffer, Mark, Wolleschak, Denise, Brüggemann, Monika, Haas, Simon, Ho, Anthony D., Müller-Tidow, Carsten, Dreger, Peter, Schmitt, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363324/
https://www.ncbi.nlm.nih.gov/pubmed/37481608
http://dx.doi.org/10.1186/s13045-023-01470-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363324/
https://www.ncbi.nlm.nih.gov/pubmed/37481608
http://dx.doi.org/10.1186/s13045-023-01470-0

Ejemplares similares